• Molecular NameProcarbazine
  • SynonymIbenzmethyzin; Ibenzmethyzine; Ibenzmethyzine hydrochloride; IBZ; MBH; MIH; MIH Hydrochloride; PCB; PCB hydrochloride; PCX; Procarbazin; Procarbazin [German]; Procarbazina [INN-Spanish]; Procarbazine hydrochloride; Procarbazinum [INN-Latin]
  • Weight221.304
  • Drugbank_IDDB01168
  • ACS_NO671-16-9
  • Show 3D model
  • LogP (experiment)0.06
  • LogP (predicted, AB/LogP v2.0)0.9
  • pka6.8
  • LogD (pH=7, predicted)0.76
  • Solubility (experiment)1.42 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.8
  • LogSw (predicted, AB/LogsW2.0)1.41
  • Sw (mg/ml) (predicted, ACD/Labs)3.24
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds5
  • TPSA53.16
  • StatusFDA approved
  • AdministrationOral (Gel Capsule), intravenous
  • PharmacologyAn antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers (such as Glioblastoma multiforme).
  • Absorption_value100.0
  • Absorption (description)Procarbazine is rapidly and completely absorbed.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmProcarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine.
  • Half life10 min
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=785 mg/kg
  • LD50 (mouse)N/A